CN110663803A - Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach - Google Patents
Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach Download PDFInfo
- Publication number
- CN110663803A CN110663803A CN201911057038.1A CN201911057038A CN110663803A CN 110663803 A CN110663803 A CN 110663803A CN 201911057038 A CN201911057038 A CN 201911057038A CN 110663803 A CN110663803 A CN 110663803A
- Authority
- CN
- China
- Prior art keywords
- euphausia superba
- polypeptide
- spleen
- biological product
- superba oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 48
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 48
- 241000239370 Euphausia superba Species 0.000 title claims abstract description 44
- 210000002784 stomach Anatomy 0.000 title claims abstract description 29
- 210000000952 spleen Anatomy 0.000 title claims abstract description 24
- 235000021190 leftovers Nutrition 0.000 claims abstract description 32
- 238000000855 fermentation Methods 0.000 claims abstract description 31
- 238000012545 processing Methods 0.000 claims abstract description 31
- 230000004151 fermentation Effects 0.000 claims abstract description 27
- 238000010564 aerobic fermentation Methods 0.000 claims abstract description 26
- 241000239366 Euphausiacea Species 0.000 claims abstract description 25
- 241000193755 Bacillus cereus Species 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000000813 microbial effect Effects 0.000 claims abstract description 21
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 15
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 15
- 241000228245 Aspergillus niger Species 0.000 claims abstract description 14
- 230000036541 health Effects 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 30
- 239000000047 product Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000004365 Protease Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 229940106134 krill oil Drugs 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 108091005804 Peptidases Proteins 0.000 claims description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 15
- 235000019419 proteases Nutrition 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 229940088598 enzyme Drugs 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 108090000145 Bacillolysin Proteins 0.000 claims description 9
- 108091005507 Neutral proteases Proteins 0.000 claims description 9
- 102000035092 Neutral proteases Human genes 0.000 claims description 9
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 6
- 235000003239 Guizotia abyssinica Nutrition 0.000 claims description 6
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 108090000526 Papain Proteins 0.000 claims description 5
- 241001052560 Thallis Species 0.000 claims description 5
- 230000009849 deactivation Effects 0.000 claims description 5
- 230000000415 inactivating effect Effects 0.000 claims description 5
- 229940055729 papain Drugs 0.000 claims description 5
- 235000019834 papain Nutrition 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000009423 ventilation Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 244000061456 Solanum tuberosum Species 0.000 claims description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 20
- 238000005516 engineering process Methods 0.000 abstract description 10
- 230000003647 oxidation Effects 0.000 abstract description 9
- 238000007254 oxidation reaction Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 238000001556 precipitation Methods 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 239000011347 resin Substances 0.000 abstract description 2
- 229920005989 resin Polymers 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- -1 ABTS free radical Chemical class 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000258957 Asteroidea Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 241000287486 Spheniscidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/001—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from waste materials, e.g. kitchen waste
- A23J1/002—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from waste materials, e.g. kitchen waste from animal waste materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/04—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from fish or other sea animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach and a preparation process thereof, and belongs to the technical field of marine organisms. The euphausia superba polypeptide biological product with remarkable spleen tonifying and stomach invigorating health care effects is developed by taking euphausia superba oil processing leftovers as raw materials and integrating the modern bioseparation technology, the biological enzymolysis technology and the mixed bacteria microbial fermentation technology, wherein the mixed bacteria aerobic fermentation strain mainly comprises aspergillus niger, bacillus subtilis and bacillus cereus. The obtained antarctic krill polypeptide has strong health care effects of benefiting spleen and invigorating stomach, and the extract can be subjected to concentration, adsorption drying, alcohol precipitation or resin purification and other treatments according to application ways, so that the efficient utilization in the fields of health care, food, medicine and the like is met. The process is simple and efficient, the obtained product has strong oxidation resistance, strong spleen-tonifying and stomach-invigorating health care effects, strong product stability and low production cost, and is easy for industrial mass production.
Description
Technical Field
The invention relates to a euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach and a preparation process thereof, in particular to a euphausia superba polypeptide biological product with high oxidation resistance prepared by synergistic fermentation of microorganisms, belonging to the technical field of marine organisms.
Background
Antarctic continents are the only uncontaminated continents on the earth, and the world that has been praised as "clean and clear" is the last piece of "clean soil" on the earth. The ocean around the Antarctic continent is called a rich and clean "marine ranch", and the ocean is filled with living organisms, where there are seaweeds, corals, starfishes and sponges, and there are many small organisms called krill, which is food on which numerous fishes, seabirds, seals, penguins and whales in Antarctic continent live, and plays an important role in the south ocean food chain. Antarctic krill is the fourth largest resource in areas following grains, petroleum, coal. The storage amount of the antarctic krill is quite remarkable, and the nutritional value is extremely high. It is the highest protein-containing organism found today, with a protein content of more than fifty percent, and also contains a great abundance of amino acids and vitamin A essential for human tissues.
At present, Antarctic krill is mainly applied to medicine and food by Antarctic krill oil. Antarctic krill oil is extracted by a patent ultralow temperature extraction method, is natural health food given to human beings by nature, and has the effect that other foods cannot be replaced. The krill oil is clinically proved to have the advantages of ultra-strong blood fat reduction, blood sugar reduction, blood pressure reduction, nutrition passing through a blood brain barrier and activation of brain cells and nerves, and prevention and treatment of cerebrovascular diseases; simultaneously, preventing and treating coronary atherosclerosis and coronary heart disease, and preventing cardiovascular diseases such as myocardial infarction, stent, bypass, secondary recurrence and the like; in addition, the antarctic krill oil can also have multiple effects of resisting bacteria and diminishing inflammation, preventing the occurrence and development of cancers, delaying fatigue, regulating endocrine and the like. With the application and popularization of the Antarctic krill oil, the processing industry develops rapidly, a large amount of Antarctic krill oil processing leftovers are generated, the composition of the leftovers is mainly protein, and therefore the mutual utilization of the resources of the Antarctic krill oil processing leftovers becomes a technical problem to be solved urgently in the field.
In the prior art, the preparation methods of antarctic krill polypeptides are relatively few, and mainly include an enzymatic hydrolysis method, for example, patent 201810373432.5 discloses a method for degrading defatted antarctic krill powder by a combinatorial enzymatic method to recover polypeptide intermediate products and prepare N-acetylglucosamine; firstly, pretreatment of the degreased antarctic krill powder is carried out, and polypeptides in the degreased antarctic krill powder are recovered through pretreatment of alkaline protease, so that raw materials are fully utilized, and the relative content of chitin in the degreased antarctic krill powder is improved. Compared with the documents, the complex enzymatic hydrolysis method is mostly adopted for the preparation of the antarctic krill polypeptide, the key technology for resource utilization of the processing leftovers of the antarctic krill oil by the fermentation of complex microorganisms and the application thereof are lacked, and especially the research for improving the nutrition of the antarctic krill polypeptide becomes the key bottleneck for restricting the industrial development.
Disclosure of Invention
In order to overcome the defects of the prior art and meet the requirements of efficient extraction of antarctic krill polypeptides and application of health-care effects of tonifying spleen and invigorating stomach, the invention provides a biological product of antarctic krill oil polypeptides capable of tonifying spleen and invigorating stomach, integrates a modern bioseparation technology, a biological enzymolysis technology and a mixed microbial fermentation technology, develops and develops the antarctic krill polypeptide biological product with remarkable effects of tonifying spleen and invigorating stomach, meets the application requirements of the fields of health care, medical treatment, food and the like on the antarctic krill polypeptides, and is simple and efficient in process, strong in oxidation resistance and health-care effects of tonifying spleen and invigorating stomach, low in production cost and easy for industrial scale production.
The invention realizes the technical effects through the following technical scheme:
a Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach is characterized by comprising the following steps:
(1) dissolving: crushing the leftovers of the euphausia superba oil processing, adding water and stirring until the leftovers are completely dissolved;
(2) enzymolysis: adding compound protease with the mass ratio of 2-3% of the tailings of the Antarctic krill oil processing after dissolving, and performing enzymolysis for 4-8 hours at the temperature of 40-60 ℃;
(3) aerobic fermentation: adding a compound microbial agent with the mass ratio of 2-3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and performing aerobic fermentation for 6-12 h at the temperature of 28-35 ℃;
(4) anaerobic fermentation: after the aerobic fermentation is finished, 1-2% of bifidobacterium bifidum powder is added, and anaerobic fermentation is carried out for 8-16 h at the temperature of 28-35 ℃;
(5) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(6) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(7) centrifuging: and (4) performing centrifugal separation at the speed of 10000r/min to obtain a supernatant, namely the antarctic krill polypeptide extracting solution.
The optimal water adding proportion in the step (1) is the tailings of the euphausia superba oil processing: water =1: 8.
Preferably, pachymaran with the mass ratio of 2-3% of the Antarctic krill oil processing leftovers is added in the Antarctic krill oil processing leftovers dissolving process.
The compound protease in the step (2) is the combination of papain and neutral protease, and the mass ratio of the compound protease to the neutral protease is 2: 1.
The compound microbial agent in the step (3) is a mixed microbial agent of aspergillus niger, bacillus subtilis and bacillus cereus, and the mass ratio of the compound microbial agent to the bacillus cereus is 2:3: 1.
The ventilation rate is 0.1-0.2 m when the aerobic fermentation process in the step (3) is carried out in a fermentation tank3/m3And min, and controlling the stirring speed to be 300-600 r/min.
The preparation method of the aspergillus niger seed liquid comprises the following steps: culturing for 24h at 35-40 deg.C in potato culture medium under aseptic condition to obtain Aspergillus niger seed liquid with effective viable count not less than 109cfu/mL。
The preparation method of the bacillus subtilis and bacillus cereus seed liquid comprises the following steps: culturing for 24h at 28-32 ℃ by adopting an LB culture medium under the aseptic condition,preparing liquid bacillus subtilis and bacillus cereus seed liquid, wherein the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL。
The obtained antarctic krill polypeptide has strong oxidation resistance and health care effects of benefiting the spleen and invigorating the stomach, and the extract can be subjected to concentration, adsorption drying, alcohol precipitation or resin purification and other treatments according to application ways, so that the efficient utilization in the fields of health care, food, medicine and the like is met.
The invention provides a euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach, which has the following remarkable advantages compared with the prior art:
(1) the processing leftover of the euphausia superba oil is used as a raw material, and the modern biological separation technology, the biological enzymolysis technology and the mixed microbial fermentation technology are integrated, so that the oxidation resistance of the processing leftover of the euphausia superba oil is obviously improved; more importantly, according to the creative discovery of the application, the spleen-tonifying and stomach-invigorating health-care effects of the antarctic krill polypeptides prepared by the enzymolysis and fermentation method can be remarkably improved by adding pachymaran in a certain proportion into the protein solution of the tailings generated in the processing of the antarctic krill oil, the analysis reason may be that the complex chemical reaction between the pachymaran and the antarctic krill polypeptides plays a role in improving the spleen-tonifying and stomach-invigorating effects, and the pachymaran can promote the fermentation effect of microorganisms, so that the oxidation resistance of the product is further improved;
(2) this application utilizes good oxygen fungus (aspergillus niger, bacillus subtilis, bacillus cereus) to ferment antarctic krill oil processing leftover bits and pieces jointly and draws antarctic krill polypeptide, and the synergism between the make full use of microorganism promotes the extraction rate and the external antioxidant capacity of antarctic krill polypeptide, wherein: aspergillus niger can generate various enzymes for degrading cell walls in the fermentation process, so that more functional active substances such as polypeptide and the like are released from the cell walls, and the in-vitro antioxidant capacity of the euphausia superba polypeptide is improved; the bacillus subtilis can kill pathogenic bacteria in fermentation liquor in the high-temperature fermentation process, has strong capabilities of producing amylase, protease and the like, and can degrade macromolecular starch and protein substances into microorganisms for utilization; although the addition of the bacillus cereus has little influence on the extraction rate of the polypeptide, the spleen-tonifying and stomach-invigorating health-care effects of the product are obviously improved;
(3) according to the invention, bifidobacterium bifidum is adopted for anaerobic fermentation, so that the stability of the euphausia superba polypeptide is improved, test results show that the temperature and the time have little influence on the oxidation resistance of the protein hydrolysis peptide of the euphausia superba oil processing leftovers within the range of 20-80 ℃, the oxidation resistance begins to be reduced along with the increase of the temperature and the time when the temperature exceeds 100 ℃, and the stability is higher than the technical level reported at present.
Detailed Description
In the present application, the activation method of Aspergillus niger and Bacillus subtilis and Bacillus cereus is as follows:
(1) the preparation method of the aspergillus niger seed liquid comprises the following steps: culturing for 24h at 35-40 deg.C in potato culture medium under aseptic condition to obtain Aspergillus niger seed liquid with effective viable count not less than 109cfu/mL；
(2) The preparation method of the bacillus subtilis and bacillus cereus seed liquid comprises the following steps: under the aseptic condition, LB culture medium is adopted to culture for 24 hours under the condition of 28-32 ℃ to prepare liquid bacillus subtilis and bacillus cereus seed liquid, and the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL。
Example 1
A Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach comprises the following specific process steps:
(1) dissolving: crushing the leftovers of the euphausia superba oil processing, adding water and stirring until the leftovers are completely dissolved; the water adding proportion is the processing leftovers of the euphausia superba oil: water =1: 8;
(2) enzymolysis: adding compound protease with the mass ratio of 3% of the Antarctic krill oil processing leftovers into the dissolved mixture, and performing enzymolysis for 6 hours at the temperature of 40-60 ℃; the compound protease is the combination of papain and neutral protease, and the mass ratio of the compound protease to the neutral protease is 2: 1;
(3) aerobic fermentation: adding a compound microbial agent with the mass ratio of 2% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 12h at the temperature of 28-35 ℃; the compound microbial agent is black kojiThe mixed microbial inoculum of the mildew, the bacillus subtilis and the bacillus cereus comprises 2:3:1 by mass; the ventilation rate is 0.1-0.2 m when the aerobic fermentation process is carried out in a fermentation tank3/m3Min, controlling the stirring speed to be 300-600 r/min;
(4) anaerobic fermentation: after the aerobic fermentation is finished, 2% bifidobacterium bifidum powder is added, and anaerobic fermentation is carried out for 8 hours at the temperature of 28-35 ℃;
(5) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(6) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(7) centrifuging: and (4) performing centrifugal separation at the speed of 10000r/min to obtain a supernatant, namely the antarctic krill polypeptide extracting solution.
Example 2
A Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach comprises the following specific process steps:
(1) dissolving: crushing the leftovers of the euphausia superba oil processing, adding water, stirring until the leftovers are completely dissolved, and adding pachyman with the mass ratio of 2% of the leftovers of the euphausia superba oil processing; the water adding proportion is the processing leftovers of the euphausia superba oil: water =1: 8;
(2) enzymolysis: adding compound protease with the mass ratio of 3% of the Antarctic krill oil processing leftovers into the dissolved mixture, and performing enzymolysis for 6 hours at the temperature of 40-60 ℃; the compound protease is the combination of papain and neutral protease, and the mass ratio of the compound protease to the neutral protease is 2: 1;
(3) aerobic fermentation: adding a compound microbial agent with the mass ratio of 2% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 12h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of aspergillus niger, bacillus subtilis and bacillus cereus, and the mass ratio of the composite microbial agent to the bacillus cereus is 2:3: 1; the ventilation rate is 0.1-0.2 m when the aerobic fermentation process is carried out in a fermentation tank3/m3Min, controlling the stirring speed to be 300-600 r/min;
(4) anaerobic fermentation: after the aerobic fermentation is finished, 2% bifidobacterium bifidum powder is added, and anaerobic fermentation is carried out for 8 hours at the temperature of 28-35 ℃;
(5) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(6) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(7) centrifuging: and (4) performing centrifugal separation at the speed of 10000r/min to obtain a supernatant, namely the antarctic krill polypeptide extracting solution.
Example 3
A Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach comprises the following specific process steps:
(1) dissolving: crushing the leftovers of the euphausia superba oil processing, adding water, stirring until the leftovers are completely dissolved, and adding pachyman with the mass ratio of 3% of the leftovers of the euphausia superba oil processing; the water adding proportion is the processing leftovers of the euphausia superba oil: water =1: 8;
(2) enzymolysis: adding compound protease with the mass ratio of 3% of the Antarctic krill oil processing leftovers into the dissolved mixture, and performing enzymolysis for 6 hours at the temperature of 40-60 ℃; the compound protease is the combination of papain and neutral protease, and the mass ratio of the compound protease to the neutral protease is 2: 1;
(3) aerobic fermentation: adding a compound microbial agent with the mass ratio of 2% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 12h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of aspergillus niger, bacillus subtilis and bacillus cereus, and the mass ratio of the composite microbial agent to the bacillus cereus is 2:3: 1; the ventilation rate is 0.1-0.2 m when the aerobic fermentation process is carried out in a fermentation tank3/m3Min, controlling the stirring speed to be 300-600 r/min;
(4) anaerobic fermentation: after the aerobic fermentation is finished, 2% bifidobacterium bifidum powder is added, and anaerobic fermentation is carried out for 8 hours at the temperature of 28-35 ℃;
(5) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(6) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(7) centrifuging: and (4) performing centrifugal separation at the speed of 10000r/min to obtain a supernatant, namely the antarctic krill polypeptide extracting solution.
Example 4 Effect of different Process conditions on antioxidant Capacity of Euphausia superba polypeptide extract
The antioxidant capacity of the euphausia superba polypeptide extract in the examples and the comparative examples is determined, wherein the OH free radical clearance is determined according to the method described in food chemical test of Shore-XiuZhi et al; ABTS free radical clearance and DPPH free radical clearance are measured by referring to the method in the method of 'influence of reaction time on oxidation resistance results evaluated by DPPH method and ABTS method' of Linlian bamboo and the like; the results of the measurement were as follows:
in the above test, the aerobic fermentation in the control 1 test group did not contain Bacillus cereus, and the rest of the experiment was the same as that in example 2. Test results show that the euphausia superba polypeptide extracting solution has remarkable antioxidant capacity, pachyman can well improve the antioxidant capacity of health products, and bacillus cereus does not have remarkable influence on the antioxidant capacity of the products.
Example 5 Effect of different Process conditions on stomach invigorating efficacy of a Marine health product for invigorating stomach
1. Test of Effect on digestive function of rat stomach
The test method comprises the following steps: selecting 40 healthy rats, and randomly dividing the rats into 6 groups according to sex and weight, wherein each group comprises 10 rats with half of male rats and half of female rats. The dosages of the medicines in the groups are prepared into 12mL, and the rat is subjected to intragastric administration (ig) once a day for 3 days according to the weight of 1.2mL/100 g. After the last ig, the rats were fasted (without water deprivation) for 24 h. Rats were anesthetized with ether, the abdominal cavity was cut, the pylorus was ligated, and the incision was closed with 1 duodenal taps. Taking out the stomach by the fold line after 3h, cutting along the large bend, pouring out the stomach contents, collecting in a graduated centrifuge tube, centrifuging at 1500r/min for 15min, and recording the stomach liquid amount. Measuring total gastric acid by a titration method, and measuring pepsin by a Mett method; control 1 the aerobic fermentation in the test group did not contain Bacillus cereus, as in example 2; control 2 the aerobic fermentation in the test group contained only bacillus cereus, as in example 2; control 3 the test group did not contain aerobic fermentation process, as in example 2.
2. Influence on intestinal motor function of mice
The test method comprises the following steps: selecting 40 healthy mice with the weight of 18-22 g, and randomly dividing the mice into 5 groups according to sex, wherein each group comprises 10 mice and each half of the mice; the above medicines are prepared into equal volume of 40mL, and each group of mice weighs 0.2mL/10g ig2 times (interval of 4 h). 1h after the last ig, according to the weight of ig charcoal powder liquid (5g charcoal powder and 1.5g shuttle methyl cellulose/100 mL), 30min after ig, taking off the cervical vertebra of the mouse, cutting off the abdominal cavity, taking out the small intestine, measuring the propelling distance of the charcoal powder and the total length of the small intestine, calculating the propelling percentage of the charcoal powder, and the test results are shown in the following table:
the experimental results show that the product has good spleen-tonifying and stomach-invigorating health care effects, and the addition of pachyman obviously improves the spleen-tonifying and stomach-invigorating health care effects of the product. The synergistic effect between the bacillus cereus and other microorganisms is more than the technical effect of '1 +1> 2'.
The above embodiments are only used for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof; such modifications and substitutions do not depart from the spirit and scope of the present invention as set forth in the appended claims.
Claims (10)
1. A Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach is characterized by comprising the following steps:
dissolving: crushing the leftovers of the euphausia superba oil processing, adding water and stirring until the leftovers are completely dissolved;
enzymolysis: adding compound protease with the mass ratio of 2-3% of the tailings of the Antarctic krill oil processing after dissolving, and performing enzymolysis for 4-8 hours at the temperature of 40-60 ℃;
aerobic fermentation: adding a compound microbial agent with the mass ratio of 2-3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and performing aerobic fermentation for 6-12 h at the temperature of 28-35 ℃;
anaerobic fermentation: after the aerobic fermentation is finished, 1-2% of bifidobacterium bifidum powder is added, and anaerobic fermentation is carried out for 8-16 h at the temperature of 28-35 ℃;
and (3) filtering: performing coarse filtration to remove fermentation thalli;
enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
centrifuging: and (4) performing centrifugal separation at the speed of 10000r/min to obtain a supernatant, namely the antarctic krill polypeptide extracting solution.
2. The Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach according to claim 1, wherein the optimal water adding ratio in the step (1) is the euphausia superba oil processing leftover: water =1: 8.
3. The biological product of euphausia superba oil polypeptide capable of benefiting spleen and strengthening stomach as claimed in claim 1, wherein pachyman is added to the euphausia superba oil processing leftover in an amount of 2-3% in the process of dissolving the euphausia superba oil processing leftover.
4. The Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach according to claim 1, wherein the compound protease in step (2) is a combination of papain and neutral protease at a mass ratio of 2: 1.
5. The Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach according to claim 1, characterized in that the compound microbial agent in step (3) is a mixed microbial agent of Aspergillus niger, Bacillus subtilis and Bacillus cereus, and the mass ratio of the compound microbial agent to the Bacillus cereus is 2:3: 1.
6. The Euphausia superba oil polypeptide biological product capable of tonifying spleen and invigorating stomach according to claim 1, wherein the ventilation rate of the aerobic fermentation process in step (3) is 0.1-0.2 m when the aerobic fermentation process is performed in a fermentation tank3/m3And min, and controlling the stirring speed to be 300-600 r/min.
7. The euphausia superba oil capable of benefiting spleen and strengthening stomach according to claim 1The polypeptide biological product is characterized in that the preparation method of the Aspergillus niger seed liquid comprises the following steps: culturing for 24h at 35-40 deg.C in potato culture medium under aseptic condition to obtain Aspergillus niger seed liquid with effective viable count not less than 109cfu/mL。
8. The Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach according to claim 1, wherein the preparation method of the seed liquid of Bacillus subtilis and Bacillus cereus comprises the following steps: under the aseptic condition, LB culture medium is adopted to culture for 24 hours under the condition of 28-32 ℃ to prepare liquid bacillus subtilis and bacillus cereus seed liquid, and the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL。
9. Euphausia superba polypeptide produced by the process of claims 1-8.
10. The Euphausia superba polypeptide of claim 9, for use in health care, food, or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911057038.1A CN110663803A (en) | 2019-11-01 | 2019-11-01 | Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911057038.1A CN110663803A (en) | 2019-11-01 | 2019-11-01 | Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110663803A true CN110663803A (en) | 2020-01-10 |
Family
ID=69085656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911057038.1A Withdrawn CN110663803A (en) | 2019-11-01 | 2019-11-01 | Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110663803A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111588037A (en) * | 2020-05-26 | 2020-08-28 | 青岛浩大生物科技工程有限责任公司 | Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) |
| CN112168950A (en) * | 2020-10-15 | 2021-01-05 | 青岛嘉智生物技术有限公司 | Repairing agent for repairing pig intestinal tract |
| CN112369493A (en) * | 2020-10-28 | 2021-02-19 | 付鹏磊 | Method for improving antioxidant capacity by resource utilization of dried scallop |
-
2019
- 2019-11-01 CN CN201911057038.1A patent/CN110663803A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111588037A (en) * | 2020-05-26 | 2020-08-28 | 青岛浩大生物科技工程有限责任公司 | Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) |
| CN112168950A (en) * | 2020-10-15 | 2021-01-05 | 青岛嘉智生物技术有限公司 | Repairing agent for repairing pig intestinal tract |
| CN112168950B (en) * | 2020-10-15 | 2022-08-02 | 青岛嘉智生物技术有限公司 | Repairing agent for repairing pig intestinal tract |
| CN112369493A (en) * | 2020-10-28 | 2021-02-19 | 付鹏磊 | Method for improving antioxidant capacity by resource utilization of dried scallop |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kandra et al. | Efficient use of shrimp waste: present and future trends | |
| AU2004276123B2 (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
| CN110663803A (en) | Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach | |
| JP5249817B2 (en) | Immunostimulated fermented food from fructan-containing food | |
| CN107625125A (en) | A kind of Tiny ecosystem eats ferment and preparation method thereof | |
| CN107488598B (en) | Burdock-based cordyceps militaris mycelium and preparation method thereof | |
| CN110495611A (en) | A kind of technique improving sea cucumber nutritional health effect | |
| CN110574930A (en) | novel process for high-value utilization of euphausia superba | |
| CN110656151A (en) | Method for improving kidney-tonifying and yang-strengthening effects of sea cucumber | |
| Tan et al. | Potential economic value of chitin and its derivatives as major biomaterials of seafood waste, with particular reference to southeast asia | |
| CN102586378A (en) | Method for extracting substances from fermented shrimp head shells | |
| WO2014194707A1 (en) | Calculus enzyme and preparation method therefor | |
| CN109288042A (en) | A kind of method and application using probiotics fermention kelp preparation malignant tumour medical food raw material | |
| KR101833043B1 (en) | Method for producing feed additive comprising fermented sea mustard and feed additive produced by the same method | |
| Michalak et al. | Functional fermented food and feed from seaweed | |
| Chattaraj et al. | A critical review on the biotechnological potential of Brewers’ waste: Challenges and future alternatives | |
| CN114617190A (en) | Functional feed protein prepared from euphausia superba and method thereof | |
| CN111588037A (en) | Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) | |
| CN106036852A (en) | Method for preparing probiotic fermented functional healthcare food with arctium lappa | |
| Molina et al. | Microbial Bioprocessing of Agri-food Wastes: Industrial Applications | |
| CN112375799A (en) | Method for improving oxidation resistance of abalone biological product | |
| CN111466569A (en) | Euphausia superba oil edible nutriment | |
| CN113957109B (en) | Industrial green production process of polystictus glycopeptide | |
| KR102671355B1 (en) | Enzymatic Hydrolysates of Defatted Perilla frutescens Residue with antioxidant activity and producing method thereof | |
| JP2019129721A (en) | Method for producing seaweed-derived lactic acid fermentation solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200110 |
|
| WW01 | Invention patent application withdrawn after publication |